Keith Flaherty, MD
Center for Melanoma
Dr. Flaherty is director of Developmental Therapies at the Massachusetts General Hospital Cancer Center. Dr. Flaherty’s research and clinical focus is therapies for melanoma and renal cell carcinoma (RCC), with a particular expertise in targeted therapies.
Dr. Flaherty comes to Mass General from the University of Pennsylvania Abramson Cancer Center where he was an assistant professor of medicine at the University of Pennsylvania School of Medicine and an adjunct professor at the Wistar Institute. Dr. Flaherty obtained his undergraduate degree from Yale University in 1993 and an MD from Johns Hopkins University in 1997. He completed his internship in medicine, followed by a residency in medicine at Brigham and Women’s Hospital in Boston through Harvard Medical School. He went on to complete a fellowship in Medical Oncology at the Hospital of the University of Pennsylvania.
Dr. Flaherty is a member of numerous scientific cancer societies and committees, and has authored many abstracts and reviews in peer-reviewed publications. He serves as a member of the editorial board for Cancer, on the medical advisory board for the Kidney Cancer Journal, and is an ad hoc contributor for journals such as the Journal of Clinical Oncology, Cancer Research, and Annals of Internal Medicine.